News

The Impact Journals news page hosts content about important news articles and press releases from our Journals and Editorial Board Members.

News

Mission
The Impact Journals news page hosts articles about important news stories from our journals and within the scientific community. Visit this page for the latest in medical advances, pharmaceutical progress, conference reports, and more.

Differential Expression of Mad2 Gene in Human Esophageal Cancer

News

February 12, 2024
PRESS RELEASE: On February 5, 2024, a new research paper was published in Oncotarget, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples.” continue reading »

IPIAD: An Augmentation to Standard Treatment of PDAC Using Five Repurposed Drugs

News

February 9, 2024
PRESS RELEASE: On February 7, 2024, a new research perspective was published in Oncoscience, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.” continue reading »

Mechanistically Based Blood Proteomic Markers in the TGF-β Pathway Stratify Risk of HCC in Patients With Cirrhosis

News

February 9, 2024
PRESS RELEASE: On February 5, 2024, a new research paper was published in Genes & Cancer, entitled, “Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.” continue reading »

PROX1/α-SMA Correlated With Colorectal Cancer Progression, Poor Outcomes and Therapeutic Resistance

News

February 7, 2024
PRESS RELEASE: A new research paper was published in Aging's Volume 16, Issue 2, entitled, “PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.” continue reading »

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

News

February 7, 2024
PRESS RELEASE: On February 5, 2024, a new research perspective was published in Oncotarget, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” continue reading »